Skip to main content

Table 1 Trial characteristics for included phase III studies of systemic anti-cancer therapy in advanced gastric, oesophageal or gastroesophageal cancer

From: Metastatic gastroesophageal cancer in older patients – is this patient cohort represented in clinical trials?

  n (Total n = 66) %
Geographic Location
 Asian 32 48
 European 15 23
 Worldwide 19 29
Disease Site
 Gastric 56 86
 Gastroesophageal Junction 3 5
 Oesophageal 6 9
Line of Treatment
  ≥ 1 42 64
  ≥ 2 21 32
  ≥ 3 3 4
Year of Publication
 1995–2004 7 12
 2005–2014 25 38
 2015- to date 34 51
Median Age of Participants 62 (Range 18–94)
Upper Age Restriction
 Yes 21 32
 No 43 65
 Not Specified 2 3
Median Cut Off Age 75 (Range 65–80)